title: Effects of monoamine reuptake inhibitors on wet-dog shakes mediated by 5-HT2A receptors in ACTH-treated rats.
abstract: We examined the influence of imipramine, a serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor, desipramine, a NA reuptake inhibitor, bupropion, a dopamine reuptake inhibitor, fluvoxamine, a selective 5-HT reuptake inhibitor, and mazindol, a catecholamine reuptake inhibitor, on a 5-HT2A receptor-mediated behavior, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced wet-dog shakes, in naive and adrenocorticotropic hormone (ACTH)-treated rats. Chronic administration of imipramine, desipramine and mazindol suppressed the number of wet-dog shakes in naive rats. Chronic ACTH (100 microg/rat, s.c.) treatment increased the number. Chronic administration of imipramine did not decrease the number of wet-dog shakes in ACTH-treated rats. On the other hand, desipramine and mazindol inhibited the increase in wet-dog shakes in ACTH-treated rats. Fluvoxamine and bupropion did not have any effect on the (+/-)-DOI-induced response in naive and ACTH-treated rats. NA reuptake inhibitors may improve the hyperfunction of 5-HT2A receptors induced by chronic ACTH treatment.
authors.affiliation: Department of Hospital Pharmacy, Okayama University Medical School, 2-5-1, Shikata-cho, Okayama, 700-8558, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kawakami
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Araki
authors.forename: Kouhei
authors.initials: K
authors.lastname: Kitagawa
authors.forename: Katsuya
authors.initials: K
authors.lastname: Suemaru
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Shibata
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Gomita
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology* / Q000633:toxicity; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D008297:Male; D014179:Neurotransmitter Uptake Inhibitors / Q000494:pharmacology / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D044402:Receptor, Serotonin, 5-HT2A / Q000502:physiology; D058830:Serotonin 5-HT2 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000633:toxicity; D014202:Tremor / Q000139:chemically induced* / Q000503:physiopathology
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000324:Adrenocorticotropic Hormone; D018765:Dopamine Uptake Inhibitors; D014179:Neurotransmitter Uptake Inhibitors; D044402:Receptor, Serotonin, 5-HT2A; D058830:Serotonin 5-HT2 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors